Developing imaging agents for detecting alpha-synuclein in Multiple System Atrophy
Imaging Ligands for Alpha-Synuclein Fibril Accumulation in Multiple System Atrophy
['FUNDING_R21'] · WASHINGTON UNIVERSITY · NIH-10581664
This study is working on a special imaging tool that can help doctors see the buildup of a protein linked to Multiple System Atrophy (MSA) in the brain, which could lead to better diagnosis and understanding of the disease for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10581664 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a PET imaging agent that can visualize the accumulation of alpha-synuclein fibrils in patients with Multiple System Atrophy (MSA). By screening various compounds for their ability to bind to these fibrils, the study aims to identify potential leads for a diagnostic tool that can accurately assess disease progression and improve diagnosis. The approach involves both in vitro testing and analysis of postmortem brain tissue to ensure specificity for MSA-related fibrils. If successful, this imaging agent could significantly enhance the understanding and management of MSA.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Multiple System Atrophy or those exhibiting symptoms consistent with this condition.
Not a fit: Patients with other neurodegenerative disorders that do not involve alpha-synuclein accumulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic accuracy and monitoring of disease progression in patients with Multiple System Atrophy.
How similar studies have performed: Previous research has shown promise in developing imaging agents for similar neurodegenerative conditions, indicating potential for success in this novel approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOTZBAUER, PAUL T — WASHINGTON UNIVERSITY
- Study coordinator: KOTZBAUER, PAUL T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease